Since MMR-deficient colorectal cancers pose a greater risk of resistance to DNA-alkylating drugs due to overexpression of MGMT or MMR-deficiency [27]–[29], it is critical to discover a chemotherapeutic strategy that can be useful for the treatment of both MMR-deficient and MMR-proficient colorectal tumors. The gene discussed is MRC1; the disease is colorectal cancer.